TNFRSF1B and cancer: Recent studies have revealed that agonism and antagonism targeting TNFR2 is an attractive candidate for cancer therapy against several tumors.17 19 20 The TR75-54.7 monoclonal antibody, which is produced by Bio X cell and reportedly blocks TNFR2 from accessing its ligands TNF-α and LT-α, is the most commonly used in published research.21 22 However, in recent years, various novel TNFR2 agonists and antagonists have been designed and constructed.